- Home
- EPD vs REGN Comparison
EPD vs REGN Comparison
Compare EPD & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPD
- REGN
- Stock Information
- Founded
- EPD 1968
- REGN 1988
- Country
- EPD United States
- REGN United States
- Employees
- EPD N/A
- REGN N/A
- Industry
- EPD Natural Gas Distribution
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- EPD Utilities
- REGN Health Care
- Exchange
- EPD Nasdaq
- REGN Nasdaq
- Market Cap
- EPD 67.9B
- REGN 59.5B
- IPO Year
- EPD 1998
- REGN 1991
- Fundamental
- Price
- EPD $30.78
- REGN $580.13
- Analyst Decision
- EPD Buy
- REGN Buy
- Analyst Count
- EPD 13
- REGN 23
- Target Price
- EPD $35.92
- REGN $795.04
- AVG Volume (30 Days)
- EPD 3.9M
- REGN 1.1M
- Earning Date
- EPD 10-30-2025
- REGN 10-28-2025
- Dividend Yield
- EPD 7.09%
- REGN 0.61%
- EPS Growth
- EPD 2.20
- REGN 5.03
- EPS
- EPD 2.68
- REGN 39.67
- Revenue
- EPD $54,756,000,000.00
- REGN $14,214,200,000.00
- Revenue This Year
- EPD N/A
- REGN N/A
- Revenue Next Year
- EPD $2.23
- REGN $4.74
- P/E Ratio
- EPD $11.48
- REGN $14.60
- Revenue Growth
- EPD N/A
- REGN 5.38
- 52 Week Low
- EPD $27.77
- REGN $476.49
- 52 Week High
- EPD $34.63
- REGN $991.24
- Technical
- Relative Strength Index (RSI)
- EPD 43.43
- REGN 52.78
- Support Level
- EPD $30.01
- REGN $564.00
- Resistance Level
- EPD $30.97
- REGN $589.08
- Average True Range (ATR)
- EPD 0.36
- REGN 17.62
- MACD
- EPD -0.06
- REGN 0.15
- Stochastic Oscillator
- EPD 42.98
- REGN 50.81
About EPD Enterprise Products Partners L.P.
Enterprise Products Partners is a master limited partnership that transports and processes natural gas, natural gas liquids, crude oil, refined products, and petrochemicals. It is one of the largest midstream companies, with operations servicing most producing regions in the continental US. Enterprise is particularly dominant in the NGL market and is one of the few MLPs that provide midstream services across the full hydrocarbon value chain.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).